Literature DB >> 33628817

Using Elevated Cholesterol Synthesis as a Prognostic Marker in Wilms' Tumor: A Bioinformatic Analysis.

Yuanbin He1, Xu Cui1, Yu Lin1, Yunjin Wang1, Dianming Wu1, Yifan Fang1.   

Abstract

BACKGROUND: Wilms tumor is the most common renal malignancy of children. Identifying factors that could predict the prognosis of patients with Wilms tumor is clinically meaningful. Many studies found tumors with elevated cholesterol synthesis that are featured with dismal prognosis. Even in some clinical trials, people with excessive dietary cholesterol intake and high plasma low-density lipoprotein levels are observed to have increased risk for cancer. However, the role of cholesterol biosynthesis in Wilms tumor has not yet been well clarified.
METHODS: RNA sequencing transcriptome data and all corresponding clinicopathological information used in our study were downloaded from the TARGET database. High-throughput sequencing (Fragments Per Kilobase of transcript per Million fragments mapped) data sets of 130 tumor samples and 6 normal samples were obtained for further analysis.
RESULTS: Wilms tumor samples with higher activity of cholesterol synthesis are characterized with worse overall survival (P < 0.05). In addition, Wilms tumor samples with mitigated activity of cholesterol synthesis are featured with better dendritic cell (DC) function and cytolytic activity (P < 0.05). Furthermore, we constructed a prognosis model based on differential expressed cholesterol synthesis-related genes (DECSG), which could predict the OS of patients with Wilms tumor accurately. KEGG and GO analysis of differential expressed genes between tumor samples with high and low cholesterol synthesis indicated that DECSGs are highly enriched in "mitosis nuclear division," "nuclear division," "chromosome segregation," "cell cycle," "Spliceosome," and "RNA transport."
CONCLUSIONS: In conclusion, our study reported increased cholesterol synthesis in Wilms tumor predicts a worse prognosis and mitigated cytolytic activity, DC function, and MHC I signature in the tumor microenvironment. We also constructed a prognosis model for predicting the OS of patients with good accuracy, which is promising in clinical translation. Future studies should focus on the detailed mechanism that caused increasing cholesterol which promotes tumor progression and undermines patients' survival.
Copyright © 2021 Yuanbin He et al.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33628817      PMCID: PMC7886595          DOI: 10.1155/2021/8826286

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  44 in total

1.  Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Authors:  Caroline Happold; Thierry Gorlia; L Burt Nabors; Sara C Erridge; David A Reardon; Christine Hicking; Martin Picard; Roger Stupp; Michael Weller
Journal:  J Neurooncol       Date:  2018-02-08       Impact factor: 4.130

2.  Metabolic reprogramming of cancer-associated fibroblasts by IDH3α downregulation.

Authors:  Daoxiang Zhang; Yongbin Wang; Zhimin Shi; Jingyi Liu; Pan Sun; Xiaodan Hou; Jian Zhang; Shimin Zhao; Binhua P Zhou; Jun Mi
Journal:  Cell Rep       Date:  2015-02-26       Impact factor: 9.423

3.  Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity.

Authors:  Peter van Galen; Volker Hovestadt; Marc H Wadsworth Ii; Travis K Hughes; Gabriel K Griffin; Sofia Battaglia; Julia A Verga; Jason Stephansky; Timothy J Pastika; Jennifer Lombardi Story; Geraldine S Pinkus; Olga Pozdnyakova; Ilene Galinsky; Richard M Stone; Timothy A Graubert; Alex K Shalek; Jon C Aster; Andrew A Lane; Bradley E Bernstein
Journal:  Cell       Date:  2019-02-28       Impact factor: 41.582

4.  Immune expression in children with Wilms tumor: a pilot study.

Authors:  E K Holl; J C Routh; A W Johnston; V Frazier; H E Rice; E T Tracy; S K Nair
Journal:  J Pediatr Urol       Date:  2019-03-20       Impact factor: 1.830

5.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

Review 6.  The genetic changes of Wilms tumour.

Authors:  Taryn Dora Treger; Tanzina Chowdhury; Kathy Pritchard-Jones; Sam Behjati
Journal:  Nat Rev Nephrol       Date:  2019-04       Impact factor: 28.314

Review 7.  Biomarkers for Wilms Tumor: A Systematic Review.

Authors:  Eugene B Cone; Stewart S Dalton; Megan Van Noord; Elizabeth T Tracy; Henry E Rice; Jonathan C Routh
Journal:  J Urol       Date:  2016-05-31       Impact factor: 7.450

8.  Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.

Authors:  Chun Chao; Steven J Jacobsen; Lanfang Xu; Lauren P Wallner; Kimberly R Porter; Stephen G Williams
Journal:  BJU Int       Date:  2013-03-06       Impact factor: 5.588

Review 9.  CAF cellular glycolysis: linking cancer cells with the microenvironment.

Authors:  Amrita Roy; Soumen Bera
Journal:  Tumour Biol       Date:  2016-04-13

10.  Identification and validation of potential prognostic gene biomarkers for predicting survival in patients with acute myeloid leukemia.

Authors:  Rui Huang; Xiwen Liao; Qiaochuan Li
Journal:  Onco Targets Ther       Date:  2017-11-02       Impact factor: 4.147

View more
  1 in total

Review 1.  Membrane lipid raft homeostasis is directly linked to neurodegeneration.

Authors:  Tobias Moll; Jack N G Marshall; Nikita Soni; Sai Zhang; Johnathan Cooper-Knock; Pamela J Shaw
Journal:  Essays Biochem       Date:  2021-12-22       Impact factor: 8.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.